The antidyslipidemic market is approaching further genericization when in 2011, leading statin brand Lipitor will lose patent exclusivity and trigger decline of the entire market value. Clinical trials continue to produce an evidence base that justifies the dominant position held by statins and extends their reach into further indications.
Key reasons to purchase this title
- Quantify and qualify antidyslipidemic sales in each of the seven major markets for 20062019
- Examine the future performance of leading antidyslipidemic brands and the growth of generics
- Understand the commercial landscape and challenges faced by pipeline agents
